Table 1

The pregnancy-related characteristics of patients with NMOSD with AQP4-ab and MOG-ab

AQP4 cohortMOG cohort
Number of patients/number of patients with pregnancies after disease onset83/5021/5
Number of informative pregnancies/number of pregnancies after disease onset108/6621/5
Number of total pregnancy-related attacks12628
Age at disease onset, year, mean±SD25.8±6.326.7±5.9
Age at delivery/abortion, year, mean±SD28.4±4.628.3±3.6
AQP4-ab or MOG-ab titre, median (range)1:32 (1:10–1:3200)1:32 (1:10–1:320)
Number of pregnancy-related attacks (%)
 DP113 (10.3)2 (7.1)
 DP29 (7.1)1 (3.6)
 DP34 (3.2)0 (0)
 PP151 (40.5)11 (39.3)
 PP225 (19.8)5 (17.9)
 PP3+424 (19.0)9 (32.1)
Number of different pregnancy outcomes or complications (%)
 Term delivery60 (55.6)18 (85.7)
 Premature delivery5 (4.6)1 (4.8)
 Elective abortion39 (36.1)2 (9.5)
 Spontaneous abortion4 (3.7)0 (0)
 Neonatal malformation3 (2.8)0 (0)
 Pre-eclampsia0 (0)0 (0)
BP-ARR mean (95% CI)0.33 (0.19 to 0.47)0.40 (0.26 to 0.54)
Adjusted BP-ARR* mean (95% CI)0.33 (0.26 to 0.41)
PP-ARR mean (95% CI)0.65 (0.46 to 0.84)0.60 (0.38 to 0.82)
Adjusted PP-ARR* mean (95% CI)0.69 (0.61 to 0.78)
  • *ARR was adjusted using a Poisson regression for treatment variables (inadequate or adequate treatment) during 12–0 months prepregnancy and during 0–12 months after delivery/abortion.

  • AQP4-ab, aquaporin-4 antibody; ARR, annualised relapse rate; BP, before pregnancy; DP, during pregnancy; MOG-ab, myelin oligodendrocyte glycoprotein antibody; NMOSD, neuromyelitis optica spectrum disorder; PP, postpartum period.;